Treatment of Graves' hyperthyroidism - Prognostic factors for outcome

Saudi Medical Journal

Volumn 28, Issue 2, 2007, Pages 225-230

  Alfadda, Assim ^a   Malabu, Usman H ^a   El Desouki, Mahmoud I ^a   Al Rubeaan, Khalid A ^a   Al Ruhaily, Atallah D ^a   Fouda, Mona A ^a   Al Maatouq, Mohamed A ^a   Sulimani, Riad A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; LIOTHYRONINE; RADIOACTIVE IODINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOCHEMISTRY; CHILD; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; FREE LIOTHYRONINE INDEX; GRAVES DISEASE; HUMAN; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; SAUDI ARABIA; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANTITHYROID AGENTS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MALE; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STATISTICS, NONPARAMETRIC; THYROID FUNCTION TESTS; THYROTROPIN; TREATMENT OUTCOME;

EID: 34147124379     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994; 330: 1731-1738.
2. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991; 1: 129-135.
3. Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 1989; 120: 689-701.
4. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7: 369-375.
5. Gittoes NJ, Franklyn JA. Hyperthyroidism. Current treatment guidelines. Drugs 1998; 55: 543-553.
6. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990; 70: 1518-1524.
7. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002; 87: 1073-1077.
8. Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA, Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001; 86: 3611-3617.
9. Becker DV, Sawin CT. Radioiodine and thyroid disease: the beginning. Semin Nucl Med 1996; 26: 155-164.
10. Saleh A, Cohnen M, Furst G, Modder U, Feldkamp J. Prediction of relapse after antithyroid drug therapy of Graves' disease: value of color Doppler sonography. Exp Clin Endocrinol Diabetes 2004; 112: 510-513.
11. Weetman AP, Ratanachaiyavong S, Middleton GW, Love W, John R, Owen GM, et al. Prediction of outcome in Graves' disease after carbimazole treatment. Q J Med 1986; 59: 409-419.
12. Winsa B, Dahlberg A, Jansson R, Agren H, Karlsson FA. Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. Acta Endocrinol (Copenh) 1990; 122: 722-728.
13. Laurberg P, Buchholtz Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J. Goitre size and outcome of medical treatment of Graves' disease. Acta Endocrinol (Copenh) 1986; 111: 39-43.
14. McGregor AM, Smith BR, Hall R, Petersen MM, Miller M, Dewar PJ. Prediction of relapse in hyperthyroid Graves' disease. Lancet 1980; 1: 1101-1103.
15. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1038-1042.
16. Werner S. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab 1977; 44: 203-204.
17. Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Br Med J (Clin Res Ed) 1984; 289: 361-363.
18. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol 2002; 147: 583-589.
19. Crivellaro, C, Oberhofer R, Leimgruber K, Amor H. Graves' disease. Clinical features and treatment results. Acta Med Austriaca 2001; 28: 47-51.
20. Mithal A, Shah A, Kumar S. The management of Graves' disease by Indian thyroidologists. Natl Med J India 1993; 6: 163-166.
21. Ward I., Huot C, Lambert R, Deal C, Collu R, Van Vliet G. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine. Clin Invest Med 1999; 22: 132-139.
22. Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ. Pediatric Graves' disease: outcome and treatment. J Pediatr Endocrinol Metab 2003; 16: 1249-1255.
23. Cunnien AJ, Hay ID, Gorman CA, Offord KP, Scanlon PW, Radioiodine-induced hypothyroidism in Graves' disease: factors associated. J Nucl Med 1982; 23: 978-983.
24. Graham GD, Burman KD. Radioiodine treatment of Graves' disease. An assessment of its potential risks. Ann Intern Med 1986; 105: 900-905.
25. Nordyke RA, Gilbert FI, Jr. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 1991; 32: 411-416.
26. Watson AB, Brownlie BE, Frampton CM, Turner JG, Rogers TG. Outcome following standardized 185 MBq dose 1311 therapy for Graves' disease. Clin Endocrinol (Oxf) 1988; 28: 487-496.
27. Sridama V, McCormick M, Kaplan EL, Faucher R, DeGroot LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med 1984; 311: 426-432.
28. Franklyn JA, Daykin J, Holder R, Sheppard MC. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism. QJM 1995; 88: 175-180.
29. Blahd WH, Hays MT. Graves' disease in the male. A review of 241 cases treated with an individually calculated dose of sodium iodide I 131. Arch Intern Med 1972; 129: 33-40.
30. 131I therapy of Graves' disease. Ann Intern Med 1977; 87: 441-443.
31. Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, et al. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf) 2004; 61: 612-618.
32. Bojarska-Szmygin A, Janicki K, Pietura R, Janicka L. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease. Ann Univ Mariae Curie Sklodowska Med 2003; 58: 248-253.
33. DeGroot LJ, Gorman CA, Pinchera A, Bartalena L, Marcocci C, Wiersinga, WM, et al. Therapeutic controversies. Retro-orbital radiation and radioactive iodide ablation of the thyroid may be good for Graves' ophthalmopathy. J Clin Endocrinol Metab 1995; 80: 339-340.
34. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338: 73-78.
35. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992; 326: 1733-1738.
36. Barralena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321: 1349-1352.
37. Dasgupta S, Savage MW. Evaluation of management of Graves' disease in District General Hospital: achievement of consensus guidelines. Int J Clin Pract 2005; 59: 1097-1100.
38. Ghadban WK, Zirie MA, Al-Khateeb DA, Jayyousi AA, Mobayedh HM, El-Aloosy AS. Radioiodine treatment of hyperthyroidism. Success rate and influence of thyrostatic medication. Saudi Med J 2003; 24: 347-351.
39. Erem C, Kandemir N, Hacihasanoglu A, Ersoz HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine 2004; 25: 55-60.